Formulation of IMXQB: Nanoparticles Based on Quillaja brasiliensis Saponins to be Used as Vaccine Adjuvants
- PMID: 35508839
- DOI: 10.1007/978-1-0716-2185-1_15
Formulation of IMXQB: Nanoparticles Based on Quillaja brasiliensis Saponins to be Used as Vaccine Adjuvants
Abstract
Adjuvants are essential components of subunit, recombinant, nonreplicating and killed vaccines, as they are substances that boost, shape, and/or enhance the immune response triggered by vaccination. Saponins obtained from the Chilean Q. saponaria tree are used as vaccine adjuvants in commercial vaccines, although they are scarce and difficult to obtain. In addition, tree felling is needed during its extraction, which has ecological impact. Q. brasiliensis leaf-extracted saponins arise as a more sustainable alternative, although its use is still limited to preclinical studies. Despite the remarkable immunostimulating properties of saponins, they are toxic to mammalian cells, due to their intrinsic characteristics. For these reasons they are mostly used in veterinary vaccines, although recently the Q. saponaria purified saponin QS-21 has been included in adjuvant systems for human vaccines, such as Mosquirix and Shingrix (GSK). In order to abrogate the toxicity of the saponins fractions, they can be formulated as immunostimulating complexes (ISCOMs). ISCOM-matrices are cage-like nanoparticles of approximately 40 nm, formulated combining saponins and lipids, without antigen, and are great adjuvants able to promote Th1-biased immune responses in a safe manner. Herein we describe how to formulate ISCOM-matrices nanoparticles using Q. brasiliensis purified saponin fractions (IMXQB) by the dialysis method. In addition, we indicate how to verify the appropriate size and homogeneity of the formulated nanoparticles.
Keywords: Adjuvants; DLS; Dialysis; HR-TEM; ISCOMs; Nanoparticles; Quillaja brasiliensis; Saponins.
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.
References
-
- O’Hagan DT, Lodaya RN, Lofano G (2020) The continued advance of vaccine adjuvants—‘we can work it out.’. Semin Immunol 50:101426. https://doi.org/10.1016/j.smim.2020.101426 - DOI - PubMed
-
- He Y, Hu Z, Li A et al (2019) Recent advances in biotransformation of saponins. Molecules 24:2365. https://doi.org/10.3390/molecules24132365 - DOI - PMC
-
- Lacaille-Dubois MA (2019) Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: a review. Phytomedicine 60:152905. https://doi.org/10.1016/j.phymed.2019.152905 - DOI - PubMed - PMC
-
- Morein B, Sundquist B, Höglund S et al (1984) Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature 308:457–460. https://doi.org/10.1038/308457a0 - DOI - PubMed
-
- Morelli AB, Becher D, Koernig S et al (2012) ISCOMATRIX: a novel adjuvant for use in prophylactic and therapeutic vaccines against infectious diseases. J Med Microbiol 61:935–943. https://doi.org/10.1099/jmm.0.040857-0 - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
